Unity Biotechnology, once a rising star in the biotech world, has laid off its entire workforce, including top executives, as it endeavours to conserve cash and evaluate potential exit strategies. The South San Francisco-based firm, known for its high-profile backing and focus on anti-aging treatments, has now hit a critical breaking point.
All remaining employees will exit by 15 May, including CEO Anirvan Ghosh, CFO, and chief legal officer.
According to filings with the US Securities and Exchange Commission, Unity plans to spend about $3.7 million on severance — a sizeable chunk of the $16.9 million it had left in reserve as of March 2025. Some of the leadership team may return temporarily as consultants to oversee clinical trial closures and look at a possibility of mergers, asset sales, or a full shutdown.
Founded in 2011, Unity gained attention with its goal to combat aging at the cellular level by targeting senescent cells. It found investors the likes of Jeff Bezos and Peter Thiel with whose help it achieved a valuation of $700 million following its IPO in 2018.
Despite early promise, the company failed to deliver successful treatments. A 2020 osteoarthritis trial missed its goals, and a 2023 eye disease trial also fell short. No drugs have reached the market. Unity reportedly posted losses to the tune of over $510 million.
While at the start of 2025, only 16 full-time employees remained, that number is now zero. The company’s hopes now rest purely on the success of diabetic eye disease treatment. However, a collaboration that is supposed to facilitate this is not yet certain.
Unity’s losses n situation today are the result of the volatile nature of the innovations in the biotech space, where visions often face huge hurdles before they become commercially viable
